Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
107.9 USD | -0.13% | +1.23% | +19.13% |
01:58pm | Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target | MT |
06/05 | Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.13% | 6.77B | |
+28.26% | 48.16B | |
-1.11% | 41.73B | |
+43.06% | 41.03B | |
-5.31% | 28.77B | |
+10.72% | 25.59B | |
-21.21% | 18.96B | |
+6.36% | 12.92B | |
+26.92% | 12.03B | |
-3.19% | 11.77B |
- Stock Market
- Equities
- BPMC Stock
- News Blueprint Medicines Corporation
- Morgan Stanley Adjusts Price Target on Blueprint Medicines to $63 From $59, Maintains Equalweight Rating